Zeus Capital leads £5m Oncimmune placing

The shares were placed with new and existing investors. £1m of these shares were placed conditional on confirmation from HMRC that these shares are regarded as a qualifying holding for the purposes of Part 6 of the Income Tax Act 2007 (the “VCT Condition”).

The fundraise will allow Oncimmune to continue to deliver on the growth strategy laid out at the time of its IPO; involving generating revenue from multiple products, regions and partners and it is confident that it is well placed to create and deliver value from its core autoantibody platform in the medium and long term.

*This web page constitutes a financial promotion for the purposes of section 21 of the Financial Services and Markets Act 2000 and has been approved by Zeus Capital Limited, which is authorised and regulated by the Financial Conduct Authority.